10 years with ICH E10: Choice of control groups

Pharmaceutical Statistics

Volumn 10, Issue 5, 2011, Pages 407-409

  Rockhold, Frank W ^a   Enas, Gregory G ^b  

^a GLAXOSMITHKLINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTIC METHOD; CLINICAL TRIAL (TOPIC); DATA ANALYSIS; ICH E10; MEDICAL RESEARCH; REVIEW; RISK BENEFIT ANALYSIS;

CLINICAL TRIALS AS TOPIC; CONTROL GROUPS; DRUG AND NARCOTIC CONTROL; GUIDELINES AS TOPIC; HUMANS; INTERNATIONALITY; PATIENT SELECTION; PLACEBOS; TIME FACTORS;

EID: 80053563345     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.500     Document Type: Review

References (26)

1. ICH E10 2000. Choice of control group in clinical trials. Available at URL: [14 May2011].
2. Ross B,. The FDA and the case for Ketek. New England Journal of Medicine April 19 2007; 356: 1601-1604.
3. Rockhold FW, Ruberg SJ,. ICH E9 reflections and considerations. Pharmaceutical Statistics October/December 2008; 7 (4): 233-235.
4. Hou Y, Wu X-Y, Li K,. Issues on the selection of non-inferiority margin in clinical trials. Chinese Medical Journal 2009; 122 (4): 466-470.
5. FDA Guidance for Industry, Non Inferiority Clinical Trials-Draft Guidance. Available at URL: [March 2010].
6. Everson-Stewart S, Emerson S,. Biocreep in Non-Inferiority Trials. Statistics in Medicine 2010; 29: 2769-2780.
7. Temple R,. Policy Developments in Regulatory Approval. Statistics in Medicine 2002; 21: 2939-2948.
8. Committee for Proprietary Medicinal Products, POINTS TO CONSIDER ON SWITCHING BETWEEN SUPERIORITY AND NON-INFERIORITY, CPMP/EWP/482/99 London, 27 July 2000.
9. Committee for Medicinal Products for Human Use, GUIDELINE ON THE CHOICE OF THE NON-INFERIORITY MARGIN, EMEA/CPMP/EWP/2158/99, 27 July 2005.
10. Peterson P, Carroll K, Chuang-Stein C, Ho YY, Jiang Q, Gang L, Sanchez M, Sax R, Wang Y-C, Snapinn S,. PISC Expert Team White Paper: Toward a Consistent Standard of Evidence When Evaluating the Efficacy of an Experimental Treatment from a Randomized Active-Control Trial". Statistics in Biopharmaceutical Research November 2010; 2 (4): 522-531.
11. Hung James HM, Wang SJ,. Comment on PISC Expert Team White Paper: Toward a Consistent Standard of Evidence When Evaluating the Efficacy of an Experimental Treatment From a Randomized Active-Controlled Trial. Statistics in Biopharmaceutical Research November 2010; 2 (4): 532-534.
12. Hung James HM, Wang SJ, O'Neill R,. Challenges and Regulatory Experiences with Non-inferiority Trial Design Without Placebo Arm. Biometrical Journal 2009; 51 (2): 324-334.
13. Snapinn S, Jiang Q,. Controlling the Type 1 Error Rate in Non-Inferiority Trials. Statistics In Medicine 2008; 27: 371-381. DOI: 10.1002/sim.3072. (Pubitemid 351227873)
14. Snapinn S, Jiang Q,. Preservation of effect and the regulatory approval of new treatments on the basis of non-inferiority trials. Statistics In Medicine 2007. DOI: 10.1002/sim.3073.
15. Fleming T,. Current issues in non-inferiority trials. Statistics In Medicine 2008; 27: 317-332. DOI: 10.1002/sim.2855. (Pubitemid 351227869)
16. Fleming T,. COMMENTARY comments on current issues in non-inferiority trials. Statistics In Medicine 2008; 27: 333-342.
17. D'Agostino RB Sr., Massaro JM, Sullivan LM,. Non-inferiority trials: design concepts and issues-the encounters of academic consultants in statistics. Statistics In Medicine 2003; 22: 169-186. (Pubitemid 36163579)
18. Ng TH,. Noninferiority hypotheses and choice of noninferiority margin. Statistics In Medicine 2008. DOI: 10.1002/sim.3367.
19. Ng TH,. Issues of simultaneous tests for noninferiority and superiority. Journal of Biopharmaceutical Statistics 2003; 13 (4): 629-639.
20. Gao P, Ware JH,. Assessing non-inferiority: a combination approach. Statistics In Medicine 2008; 27: 392-406. (Pubitemid 351227875)
21. Carroll KJ,. Active-controlled, non-inferiority trials in oncology: arbitrary limits, infeasible sample sizes and uninformative data analysis. Is there another way? Pharmaceutical Statistics 2006; 5: 283-293. (Pubitemid 46023757)
22. Julious S, Wang SJ,. How biased are indirect comparisons, particularly when comparisons are made over time in clinical trials. Drug Information Journal 2008; 42: 625-633.
23. Rohmel J, Pigeot I,. A Comparison of multiple testing procedures for the gold standard non-inferiority trial. Journal of Biopharmaceutical Statistics 2010; 20 (5): 911-926.
24. Wiens BL, Zhao W,. The role of intention to treat in analysis of noninferiority studies. Clinical Trials 2007; 4: 286-291. (Pubitemid 47400540)
25. Sorbello A, Komo S, Valappil T,. Noninferiority margin for clinical trials of antibacterial drugs for nosocomial pneumonia. Drug Information Journal 2010; 44: 165-176.
26. Guidance for Industry-Diabetes Mellitus-Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes, FDA Division of Metabolism and Endocrinology Products in the Center for Drug Evaluation and Research, 2008.